Significant variability in symptoms and disease burden exists among myasthenia gravis patients across MGFA classes, challenging the use of MGFA classification for individual prognosis. Many patients ...
SAVANNAH, Ga. -- Inebilizumab (Uplizna) had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed ...
Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results